Novo Nordisk ( NVO -2.98%) stock is in a funk. Shares of the GLP-1 diet drug manufacturer have been sliding all week long, ...

Novo Nordisk's sales and profits were both up around 30% last quarter. Its GLP-1 weight loss drug has been a driving force ...

The decliners were Novo Nordisk (NYSE: NVO), famously the company behind Wegovy, and Viking Therapeutics (NASDAQ: VKTX), which is far along in its development of an advanced GLP-1-based obesity ...

Health-care companies rose after strong earnings from one major drug maker. Novo Nordisk shares rose sharply after the Danish obesity-drug maker posted fourth-quarter Ozempic sales of $4.71 ...

Research into developing new antimicrobial resistance treatment in Nigeria and other low/middle-income countries has fuelled ...

Novo Nordisk shares rose as investors breathed a sigh of relief on strong sales growth and guidance despite ongoing capacity constraints and fears over the U.S. demand outlook for its blockbuster ...

Novo Nordisk’s CEO toasted the company’s record-breaking profitability and earnings on Wednesday morning as the group behind Ozempic and Wegovy put on a brave face about its ability to fight ...

No Plan to Prop up Global Health, Novo Nordisk Foundation Says, as Trump Freezes US Aid By Jennifer Rigby LONDON (Reuters) - The Novo Nordisk Foundation does not plan to step in to prop up a ...

The decliners were Novo Nordisk (NYSE: NVO), famously the company ... Before you buy stock in Hims & Hers Health, consider this: The Motley Fool Stock Advisor analyst team just identified what ...